Itolizumab

• CAT Number: I042529
• CAS Number: 1116433-11-4
• Purity: ≥95%

Itolizumab (Cat No.: I042529) is a humanized IgG1 monoclonal antibody targeting CD6, a co-stimulatory receptor on T cells involved in immune regulation. By modulating CD6 signaling, it reduces T cell activation and inflammation. Itolizumab has been approved in India for treating chronic plaque psoriasis and has shown promise in autoimmune conditions like rheumatoid arthritis and COVID-19-related cytokine release syndrome. Its mechanism offers a novel approach to immunomodulation with fewer side effects compared to traditional immunosuppressants, making it valuable in therapeutic immunology.

Reference

[1]. Saavedra D, et al. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing. 2020 Nov 14;17(1):34.
[Content Brief]

[2]. Loganathan S, et al. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther. 2020 Sep;20(9):1025-1031.
[Content Brief]

[3]. Srivastava A. Itolizumab in Psoriasis. Indian J Dermatol. 2017 Jul-Aug;62(4):418-421.
[Content Brief]

[4]. Freitas RF, et al. Modulation of CD4 T cell function via CD6-targeting. EBioMedicine. 2019 Sep;47:427-435.
[Content Brief]

[5]. Globig AM, et al. High-dimensional profiling reveals Tc17 cell enrichment in active Crohn’s disease and identifies a potentially targetable signature. Nat Commun. 2022 Jun 27;13(1):3688.
[Content Brief]

[6]. Bughani U, et al. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One. 2017 Jul 3;12(7):e0180088.
[Content Brief]

[7]. Cherie Tracy Ng, et al. Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease. Blood (2019) 134 (Supplement_1): 5603.